Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells.
B7/CTLA-4 interactions negatively regulate T-cell responses and are necessary for transplant tolerance induction. Tolerance induction may therefore be facilitated by selectively inhibiting the B7/CD28 pathway without blocking that of B7/CTLA-4. In this study, we selectively inhibited CD28/B7 interactions using a monoclonal antibody modulating CD28 in a rat model of acute kidney graft rejection. A short-term treatment abrogated both acute and chronic rejection. Tolerant recipients presented few alloantibodies against donor MHC class II molecules, whereas untreated rejecting controls developed anti-MHC class I and II alloantibodies. PBMC from tolerant animals were unable to proliferate against donor cells but could proliferate against third-party cells. The depletion of B7+, non-T cells fully restored this reactivity whereas purified T cells were fully reactive. Also, NK cells depletion restored PBMC reactivity in 60% of tolerant recipients. Conversely, NK cells from tolerant recipients dose-dependently inhibited alloreactivity. PBMC anti-donor reactivity could be partially restored in vitro by blocking indoleamine-2,3-dioxygenase (IDO) and iNOS. In vivo, pharmacologic inhibition of these enzymes led to the rejection of the otherwise tolerated transplants. This study demonstrates that an initial selective blockade of CD28 generates B7+ non-T regulatory cells and a kidney transplant tolerance sustained by the activity of IDO and iNOS.
Haspot
Fabienne
F
ITERT-INSERM U643, CHU Hôtel Dieu, 30, Bd Jean Monnet, 44093 Nantes, France.
Séveno
Céline
C
Dugast
Anne-Sophie
AS
Coulon
Flora
F
Renaudin
Karine
K
Usal
Claire
C
Hill
Marcelo
M
Anegon
Ignacio
I
Heslan
Michèle
M
Josien
Régis
R
Brouard
Sophie
S
Soulillou
Jean-Paul
JP
Vanhove
Bernard
B
D000818:Animals; D017209:Apoptosis; D018122:B7-1 Antigen / Q000096:biosynthesis*; D018106:CD28 Antigens / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology; D049109:Cell Proliferation; D016207:Cytokines; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis*; D007150:Immunohistochemistry; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors; D007518:Isoantibodies / Q000737:chemistry; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D010641:Phenotype; D051381:Rats; D011917:Rats, Inbred Lew; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D023001:Transplantation Tolerance; D014364:Tryptophan / Q000378:metabolism*
D018122:B7-1 Antigen; D018106:CD28 Antigens; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007518:Isoantibodies; D011948:Receptors, Antigen, T-Cell; D014364:Tryptophan; D052247:Nitric Oxide Synthase Type II